|
|
 |
|
Viewing report
|
|
|
|
Emerging Generic Pharmaceuticals Markets in Europe
Frost & Sullivan, Dec 2008, Pages: 75
This research service analyses and provides growth opportunities in the Emerging Generics Pharmaceuticals Market in Europe. It analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts has been discussed. It also provides strategic recommendations.
This Frost & Sullivan research service titled Emerging Generic Pharmaceuticals Markets in Europe provides an in-depth examination of drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the generic pharmaceuticals markets in Italy, Portugal, Spain and France.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.
Market Overview
Restricted Healthcare Budgets Push Popularity of Generics
Government and healthcare authorities in Europe, concerned with the rising cost of pharmaceuticals, are striving to promote the use of generics over high-priced originator drugs. This strategy will help meet their constrained healthcare budgets. However, pricing and reimbursement policies in Europe are very complex; each country has its own set of policies governing generics. This is leading to uneven penetration of generics. The launch and uptake of generics is being delayed due to the lack of coherent reimbursement and substitution policies across Europe.
“A coherent and uniform generics policy should be implemented across all European countries,” states the analyst of this research. “It should primarily address both supply-side (pricing and reimbursement) as well as demand-side (physicians, pharmacists and patients) factors.” In addition, healthcare authorities and generics industry participants should take various measures to convince physicians, pharmacists and patients of the bio-equivalence of generic and originator medicines. Regulatory issues in the emerging generic pharmaceuticals markets of Italy, Portugal, Spain and France are in the process of being streamlined in order to fuel the adoption of generics. Reforms are underway in these countries to draw level with highly genericised countries such as the United Kingdom. Burdened by cost constraints and faced with the rising cost of pharmacueticals, governments and healthcare authorities in key underpenetrated countries (Spain, France, Italy and Portugal) are supporting the use of generics over high-priced originator drugs. Continuing patent expiries are also feeding the generics pipeline.
Uneven Pricing and Reimbursement Pose Challenges
European pricing and reimbursement policy is very complex. Each country has its own set of policies governing generics, which is leading to uneven generics penetration. Further, physicians in most under-penetrated European countries prefer innovator drugs to generics. “The launch and uptake of generics is being delayed due to the lack of reimbursement and substitution policies,” says the analyst of this research. “Variations in pricing and reimbursement approvals hinder the development of a competitive European generic pharmaceuticals industry.”
A consistent generics policy should be implemented across all European countries. This would aid in the development of a competitive generic pharmaceuticals market. “Such a policy should account for both the supply-side as well as the demand-side,” advises the analyst of this research. “In addition, healthcare authorities and generics industry participants should undertake various measures to convince physicians, pharmacists and patients of the bio-equivalence of generic and originator drugs.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pharmaceutical Pricing and Reimbursement in Spain, 2008
Pricing and Reimbursement Issues for Generics and Biosimilars
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
Generic Pharmaceuticals Market – A Global Analysis
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Pharmaceutical Market Access in Europe: The Barriers Keep On Rising
Pharmaceutical Cost Containment in Europe: National Governments Tighten the Screws
Italy Pharmaceutical Market Overview Generic penetration set to rise
Pharmaceutical Pricing, Reimbursement and Market Access News in the First Quarter of 2010
|
|
|
|
